Genzyme: Researchers gather more data than needed; ARCA, FDA reach agreement on trial design;

> "I think it is clear that a lot of studies are conducted with more information than is actually needed; therefore, stripped down models of studies have increasingly greater potential for use in the future," says Genzyme VP Paul Beninger.  Report

> ARCA and the FDA have agreed on a protocol that calls for two interim data analyses in a trial for bucindolol, a beta-blocker and vasodilator candidate. If results of either analysis meet spec, they could serve as the clinical effectiveness basis for FDA approval. Announcement

> The OmniComm TrialMaster EDC solution has been at work since 2005 in support of the recently approved Alair Bronchial Thermoplasty System for asthma treatment. Release

> Oracle Argus Safety has triumphed in CRO Quanticate's selection of a database for pharmacovigilance. Article

> Version 8.8 of the Velos eResearch EDC system debuted at the company's annual meeting last week, boasting bio specimen management and enhanced financial management capabilities. Release

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.